Some people hate the whole concept of marijuana because if it does bad for the children,

it does bad for people that are older than children.

But we're looking at reclassification and we'll make a determination over the next, I would

say over the next few weeks.

That was President Trump last week, promising answers soon on a major potential shift in national

drug policy.

John Yang is here with what that long anticipated change could mean for marijuana users,

businesses and research.

John?

Jeff, the Federal Drug Enforcement Administration puts drugs into five categories, what are called

schedules.

It's based on their medical value and potential for abuse and addiction.

Right now, marijuana is in the most restrictive

category, Schedule 1. That's the same category as heroin and LSD. Schedule 2 includes fentanyl and cocaine,

3, Tylenol with codeine, steroids, and testosterone, 4, Xanax and Valium, and 5 over-the-counter medications like Robitussin.

Last year, the Biden administration proposed moving marijuana from Schedule 1 to Schedule 3.

That wouldn't make it legal on the federal level, but would ease federal restrictions.

Bo Kilmer is the co-director of RAND's Drug Policy Research Center.

Mr. Kilmer, I want to examine what this would do, moving from one to three, what do we do for

various groups?

First of all, what would it do for individuals, whether they're using marijuana recreationally

or for medicinal purposes?

...